435 related articles for article (PubMed ID: 30911134)
21. Coevolving JAK2V617F+relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case.
Penter L; Gohil SH; Huang T; Thrash EM; Schmidt D; Li S; Severgnini M; Neuberg D; Hodi FS; Livak KJ; Zeiser R; Bachireddy P; Wu CJ
Blood Adv; 2021 Nov; 5(22):4701-4709. PubMed ID: 34432868
[TBL] [Abstract][Full Text] [Related]
22. Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells.
van Luijn MM; van den Ancker W; Chamuleau ME; Zevenbergen A; Westers TM; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
Cancer Res; 2011 Apr; 71(7):2507-17. PubMed ID: 21310823
[TBL] [Abstract][Full Text] [Related]
23. Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells.
Rimando JC; Chendamarai E; Rettig MP; Jayasinghe R; Christopher MJ; Ritchey JK; Christ S; Kim MY; Bonvini E; DiPersio JF
Blood; 2023 Apr; 141(14):1718-1723. PubMed ID: 36563336
[TBL] [Abstract][Full Text] [Related]
24. Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.
Hattori N; Nakamaki T
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027331
[TBL] [Abstract][Full Text] [Related]
25. A novel nonradioactive CFDA assay to monitor the cellular immune response in myeloid leukemia.
Yang T; Chen ZZ; Kolb HJ; Buhmann R
Immunobiology; 2013 Apr; 218(4):548-53. PubMed ID: 22883564
[TBL] [Abstract][Full Text] [Related]
26. Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen.
Manjappa S; Bhamidipati PK; Stokerl-Goldstein KE; DiPersio JF; Uy GL; Westervelt P; Liu J; Schroeder MA; Vij R; Abboud CN; Fehniger TA; Cashen AF; Pusic I; Jacoby M; Meera SJ; Romee R
Biol Blood Marrow Transplant; 2014 Jan; 20(1):46-52. PubMed ID: 24120526
[TBL] [Abstract][Full Text] [Related]
27. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
Williams P; Basu S; Garcia-Manero G; Hourigan CS; Oetjen KA; Cortes JE; Ravandi F; Jabbour EJ; Al-Hamal Z; Konopleva M; Ning J; Xiao L; Hidalgo Lopez J; Kornblau SM; Andreeff M; Flores W; Bueso-Ramos C; Blando J; Galera P; Calvo KR; Al-Atrash G; Allison JP; Kantarjian HM; Sharma P; Daver NG
Cancer; 2019 May; 125(9):1470-1481. PubMed ID: 30500073
[TBL] [Abstract][Full Text] [Related]
28. PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity.
van Ens D; Mousset CM; Hutten TJA; van der Waart AB; Campillo-Davo D; van der Heijden S; Vodegel D; Fredrix H; Woestenenk R; Parga-Vidal L; Jansen JH; Schaap NPM; Lion E; Dolstra H; Hobo W
Bone Marrow Transplant; 2020 Dec; 55(12):2308-2318. PubMed ID: 32528120
[TBL] [Abstract][Full Text] [Related]
29. Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation.
Crucitti L; Crocchiolo R; Toffalori C; Mazzi B; Greco R; Signori A; Sizzano F; Chiesa L; Zino E; Lupo Stanghellini MT; Assanelli A; Carrabba MG; Marktel S; Marcatti M; Bordignon C; Corti C; Bernardi M; Peccatori J; Bonini C; Fleischhauer K; Ciceri F; Vago L
Leukemia; 2015 May; 29(5):1143-52. PubMed ID: 25371177
[TBL] [Abstract][Full Text] [Related]
30. Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect.
Orti G; Barba P; Fox L; Salamero O; Bosch F; Valcarcel D
Exp Hematol; 2017 Apr; 48():1-11. PubMed ID: 28027963
[TBL] [Abstract][Full Text] [Related]
31. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
[TBL] [Abstract][Full Text] [Related]
32. How important is NK alloreactivity and KIR in allogeneic transplantation?
Shaffer BC; Hsu KC
Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
[TBL] [Abstract][Full Text] [Related]
33. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
[TBL] [Abstract][Full Text] [Related]
34. A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.
Zhang M; Sukhumalchandra P; Enyenihi AA; St John LS; Hunsucker SA; Mittendorf EA; Sergeeva A; Ruisaard K; Al-Atrache Z; Ropp PA; Jakher H; Rodriguez-Cruz T; Lizee G; Clise-Dwyer K; Lu S; Molldrem JJ; Glish GL; Armistead PM; Alatrash G
Clin Cancer Res; 2013 Jan; 19(1):247-57. PubMed ID: 23147993
[TBL] [Abstract][Full Text] [Related]
35. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.
Chapuis AG; Egan DN; Bar M; Schmitt TM; McAfee MS; Paulson KG; Voillet V; Gottardo R; Ragnarsson GB; Bleakley M; Yeung CC; Muhlhauser P; Nguyen HN; Kropp LA; Castelli L; Wagener F; Hunter D; Lindberg M; Cohen K; Seese A; McElrath MJ; Duerkopp N; Gooley TA; Greenberg PD
Nat Med; 2019 Jul; 25(7):1064-1072. PubMed ID: 31235963
[TBL] [Abstract][Full Text] [Related]
36. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
[TBL] [Abstract][Full Text] [Related]
37. Clinical Grade Production of Wilms' Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation.
Plantinga M; Lo Presti V; de Haar CG; Dünnebach E; Madrigal A; Lindemans CA; Boelens JJ; Nierkens S
Front Immunol; 2020; 11():559152. PubMed ID: 33101274
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic hematopoietic cell transplantation for adult patients with treatment-related acute myeloid leukemia during first remission: Comparable to de novo acute myeloid leukemia.
Tang FF; Huang XJ; Zhang XH; Chen H; Chen YH; Han W; Chen Y; Wang FR; Wang Y; Wang JZ; Yan CH; Sun YQ; Mo XD; Liu KY; Xu LP
Leuk Res; 2016 Aug; 47():8-15. PubMed ID: 27239735
[TBL] [Abstract][Full Text] [Related]
39. Recognition of leukemic blasts by HLA-DPB1-specific cytotoxic T cell clones: a perspective for adjuvant immunotherapy post-bone marrow transplantation.
Ibisch C; Gallot G; Vivien R; Diez E; Jotereau F; Garand R; Vié H
Bone Marrow Transplant; 1999 Jun; 23(11):1153-9. PubMed ID: 10382955
[TBL] [Abstract][Full Text] [Related]
40. Potential Beneficial Effects of Cytomegalovirus Infection after Transplantation.
Litjens NHR; van der Wagen L; Kuball J; Kwekkeboom J
Front Immunol; 2018; 9():389. PubMed ID: 29545802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
